THE BUDGET IMPACT OF INTRODUCING A PD-L1 ASSAY TO SELECT PATIENTS WITH METASTATIC NSCLC WHO ARE POTENTIAL CANDIDATES FOR TREATMENT WITH IMMUNE CHECKPOINT INHIBITORS

被引：1
|
作者：
Sheppard, B. [1 ]
Ahlsten, M. [1 ]
Paolini, D. [2 ]
Xenakis, J. [3 ]
Zhang, W. [3 ]
机构：
[1] Roche Tissue Diagnost, Tucson, AZ USA
[2] Roche Diagnost SpA, Monza, AZ USA
[3] WG Grp, New York, NY USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.1007
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PMD22
引用
收藏
页码：A576 / A576
页数：1
相关论文
共 50 条
  • [1] Soluble PD-L1 in NSCLC Patients Treated with Checkpoint Inhibitors
    Castello, A.
    Rossi, S.
    Toschi, L.
    Lopci, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S66 - S67
  • [2] Prognostic value of serum proteomic signature in NSCLC patients on immune checkpoint inhibitors: Impact of treatment regimen and PD-L1 levels
    Kim, Leeseul
    Um, Taegyu
    Chae, Young Kwang
    Cho, Allen
    CANCER RESEARCH, 2024, 84 (06)
  • [3] Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US
    Aguiar, Pedro, Jr.
    De Mello, Ramon
    Tadokoro, Hakaru
    Babiker, Hani
    Gutierres, Barbara
    Lopes, Gilberto
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S308 - S308
  • [4] Cost effectiveness and estimate of economical impact of immune checkpoint inhibitors for NSCLC relative to PD-L1 expression
    Aguiar Junior, P. N.
    De Mello, R.
    Tadokoro, H.
    Babiker, H. M.
    Lopes, G., Jr.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Plasma soluble PD-1/PD-L1 for prediction of prognosis in NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    CANCER SCIENCE, 2024, 115 : 1381 - 1381
  • [6] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Himuro, Hidetomo
    Nakahara, Yoshiro
    Igarashi, Yuka
    Kouro, Taku
    Higashijima, Naoko
    Matsuo, Norikazu
    Murakami, Shuji
    Wei, Feifei
    Horaguchi, Shun
    Tsuji, Kayoko
    Mano, Yasunobu
    Saito, Haruhiro
    Azuma, Koichi
    Sasada, Tetsuro
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023, 72 (08) : 2829 - 2840
  • [7] Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors
    Hidetomo Himuro
    Yoshiro Nakahara
    Yuka Igarashi
    Taku Kouro
    Naoko Higashijima
    Norikazu Matsuo
    Shuji Murakami
    Feifei Wei
    Shun Horaguchi
    Kayoko Tsuji
    Yasunobu Mano
    Haruhiro Saito
    Koichi Azuma
    Tetsuro Sasada
    Cancer Immunology, Immunotherapy, 2023, 72 : 2829 - 2840
  • [8] Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors
    Nakahara, Y.
    Himuro, H.
    Igarashi, Y.
    Kouro, T.
    Higashijima, N.
    Matsuo, N.
    Murakami, S.
    Wei, F.
    Horaguchi, S.
    Tsuji, K.
    Mano, Y.
    Saito, H.
    Azuma, K.
    Naoki, K.
    Sasada, T.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S614 - S614
  • [9] Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors
    Maiorano, Brigida Anna
    Di Maio, Massimo
    Cerbone, Linda
    Maiello, Evaristo
    Procopio, Giuseppe
    Roviello, Giandomenico
    JAMA NETWORK OPEN, 2024, 7 (03) : E241215
  • [10] A BUDGET IMPACT ANALYSIS OF ATEZOLIZUMAB MONOTHERAPY FOR FIRST LINE TREATMENT OF PATIENTS WITH PD-L1 HIGH METASTATIC NSCLC IN ITALY
    Pradelli, L.
    Bellone, M.
    Heaton, E.
    Celik, H.
    Caputo, A.
    Belfiore, M.
    VALUE IN HEALTH, 2022, 25 (01) : S54 - S54
12345